F. Hoffmann-La Roche Ltd reported that group sales increased by +6% at constant exchange rates and +1% in Swiss francs, reaching CHF 46,493 million in the first nine months of 2026, driven by high demand for innovative medicines and diagnostics. In US dollars, group sales rose by +7%. During the third quarter, group sales grew by +7% at constant exchange rates and +8% in Swiss francs, as currency rates stabilized.
The pharmaceuticals division increased its sales by +7% at constant exchange rates to CHF 36,212 million during the first nine months of the year, representing +2% in Swiss francs and +8% in US dollars. Growth was led by medicines targeting severe conditions, with the primary drivers being Xolair for chronic urticaria and food allergies, Hemlibra for hemophilia A, Ocrevus for multiple sclerosis, Phesgo for breast cancer, and Vabysmo for severe eye diseases. Together, these five products generated sales of CHF 16.8 billion, marking a +12% increase at constant exchange rates compared to the first nine months of 2025.
Sales of products with expired patents, including Avastin, Herceptin, MabThera/Rituxan, Lucentis, and Actemra/RoActemra, declined by CHF 0.4 billion at constant exchange rates and by CHF 0.6 billion on a Swiss franc basis. In the United States, pharmaceutical sales grew by +5% at constant exchange rates, supported by Xolair, Hemlibra, Ocrevus, Polivy, and Tecentriq, which offset lower sales for Kadcyla and Perjeta. European sales increased by +2% at constant exchange rates, driven by demand for Ocrevus, Phesgo, and Evrysdi, counterbalancing declines in Actemra/RoActemra from biosimilar competition and Perjeta from transitions to Phesgo. In Japan, sales advanced by +25% at constant exchange rates, supported by third-party product deliveries, growth in Lunsumio, Hemlibra, Polivy, Elevidys, and Vabysmo, alongside timing effects from an enterprise resource planning system rollout. International region sales rose by +10% at constant exchange rates.
The diagnostics division reported a +4% increase in sales at constant exchange rates to CHF 10,281 million for the first nine months, remaining flat in Swiss francs and up +6% in US dollars. Demand for core laboratory and pathology solutions offset the impact of pricing reforms within the Chinese healthcare system.
Regulatory developments included US approvals for Tecentriq in adjuvant stage III colorectal cancer with mismatch repair deficiency, for Gazyva/Gazyvaro to reduce relapse risk in patients aged two years and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome starting in childhood, and for Enspryng in thyroid eye disease. Accelerated review was granted in the US for Fenebrutinib in relapsing and primary progressive multiple sclerosis, and for Enspryng in MOGAD, alongside the acceptance of a filing for Vamikibart in uveitic macular edema. In Europe, approvals were secured for Susvimo in neovascular age-related macular degeneration and for Ocrevus in pediatric and adolescent relapsing multiple sclerosis, alongside European Medicines Agency validation for Enspryng in MOGAD.
Positive phase III trial results were recorded for sefaxersen in an autoimmune kidney disease, lunsumio in blood cancer, and tam-peli in relapsing small cell lung cancer, alongside phase II results for enicepatid and petrelintid in obesity and type 2 diabetes. The US Food and Drug Administration approved the Elecsys pTau217 blood test for Alzheimer-associated amyloid pathology detection, and two real-time PCR tests were launched for Cyclospora cayetanensis outbreaks in the US, while molecular diagnostics were supplied for Ebola response efforts in the Democratic Republic of Congo. Infrastructure expansion included facilities in Hillsboro, an Innovation Center in Boston, and a synthetic molecule plant in Basel, Switzerland.
Chief Executive Officer Thomas Schinecker noted that the company advanced five potential new medicines into late-stage clinical development this year, aiming to bring up to 20 new medications to patients by 2030. Roche confirmed its outlook for the full year 2026, expecting group sales to increase in the mid-single-digit range at constant exchange rates, with core earnings per share targeted to grow in the high single-digit range, alongside an ambition to raise the dividend in Swiss francs.
